Tech Company Financing Transactions
NeoSync Funding Round
NeoSync closed a $13 million Series D investment round on 8/11/2017. Investors included private investors and Valiance Life Science Investments.
Transaction Overview
Company Name
Announced On
8/11/2017
Transaction Type
Venture Equity
Amount
$13,000,000
Round
Series D
Investors
Proceeds Purpose
The company intends to use the funds for the planned registration study of NEST Technology in patients with Treatment Resistant Depression (TRD) and preparation for future commercial release of this novel technology.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
800 W Cummings Park 2650
Woburn, MA 01801
USA
Woburn, MA 01801
USA
Phone
Website
Email Address
Overview
NeoSync is a clinical-stage company with a proprietary platform technology being used to develop advanced, non-invasive neuromodulation products designed to treat Major Depressive Disorder and other diseases of the Central Nervous System (e.g. Autism, Parkinson's Disease, Anxiety, Post Traumatic Stress Disorder, etc.).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
?Lawrence Best
Chief Executive Officer
Kate Rumrill
Browse more venture capital transactions:
Prev: 8/11/2017: Netlify venture capital transaction
Next: 8/11/2017: Datarista venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs